Sigyn Therapeutics annual debt-to-assets ratio
2015
2017
2018
2019
2020
2021
2022
2023
2024
Sigyn Therapeutics Debt-to-Assets Ratio Growth & History (SIGY)
Sigyn Therapeutics's debt-to-assets ratio was 10.87 for fiscal 2024.
View full Sigyn Therapeutics company overviewSigyn Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 10.87 | 2.49 | +29.76% |
| 2023 | 2023-12-31 | 8.37 | 2.74 | +48.50% |
| 2022 · Dec 31 | 2022-12-31 | 5.64 | 4.32 | +328.89% |
| 2021 | 2021-12-31 | 1.31 | 0.57 | +75.96% |
| 2020 | 2020-12-31 | 0.75 | −2.06 | −73.36% |
| 2019 | 2019-12-31 | 2.81 | 0.80 | +39.67% |
| 2018 | 2018-12-31 | 2.01 | 1.42 | +243.06% |
| 2017 | 2017-12-31 | 0.59 | — | — |
| 2015 | 2015-12-31 | 0.01 | — | — |
Sigyn Therapeutics quarterly debt-to-assets ratio
Q4.15
Q1.16
Q2.16
Q3.16
Q4.17
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q2.22
Q1.23
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | 28.43 | 23.43 | +468.41% |
| Q2 2025 | 2025-06-30 | 53.16 | 46.39 | +685.08% |
| Q1 2025 | 2025-03-31 | 11.15 | 2.00 | +21.90% |
| Q4 2024 | 2024-12-31 | 10.87 | 2.49 | +29.76% |
| Q3 2024 | 2024-09-30 | 5.00 | −5.30 | −51.42% |
| Q2 2024 | 2024-06-30 | 6.77 | −2.26 | −24.99% |
| Q1 2024 | 2024-03-31 | 9.15 | — | — |
| Q4 2023 | 2023-12-31 | 8.37 | — | — |
| Q2 2023 | 2023-09-30 | 10.30 | — | — |
| Q1 2023 | 2023-06-30 | 9.03 | 5.13 | +131.66% |
| Q2 2022 | 2022-06-30 | 3.90 | 3.44 | +754.70% |
| Q4 2021 | 2021-12-31 | 1.31 | 0.57 | +75.96% |
| Q3 2021 | 2021-09-30 | 0.68 | −2.27 | −76.99% |
| Q2 2021 | 2021-06-30 | 0.46 | −2.43 | −84.19% |
| Q1 2021 | 2021-03-31 | 0.95 | −1.89 | −66.51% |
| Q4 2020 | 2020-12-31 | 0.75 | −2.06 | −73.36% |
| Q3 2020 | 2020-09-30 | 2.94 | 0.62 | +26.84% |
| Q2 2020 | 2020-06-30 | 2.89 | 0.72 | +33.11% |
| Q1 2020 | 2020-03-31 | 2.84 | 0.74 | +35.27% |
| Q4 2019 | 2019-12-31 | 2.81 | 0.80 | +39.67% |
| Q3 2019 | 2019-09-30 | 2.32 | — | — |
| Q2 2019 | 2019-06-30 | 2.17 | — | — |
| Q1 2019 | 2019-03-31 | 2.10 | — | — |
| Q4 2018 | 2018-12-31 | 2.01 | 1.42 | +243.06% |
| Q4 2017 | 2017-12-31 | 0.59 | — | — |
| Q3 2016 | 2016-09-30 | 0.42 | — | — |
| Q2 2016 | 2016-06-30 | 0.26 | — | — |
| Q1 2016 | 2016-03-31 | 0.12 | — | — |
| Q4 2015 | 2015-12-31 | 0.01 | — | — |
Sigyn Therapeutics debt-to-assets ratio trends
Over the last five fiscal years, Sigyn Therapeutics's debt-to-assets ratio increased from 2.81 to 10.87, a change of 8.06. The latest reported quarter, Q3 2025, shows 28.43.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sigyn Therapeutics source filings ↗